<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0056">
 <label>56</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Ramanathan</surname>
    <given-names>RK</given-names>
   </name>, 
   <name name-style="western">
    <surname>Stephenson</surname>
    <given-names>JJ</given-names>
   </name>, 
   <name name-style="western">
    <surname>Weiss</surname>
    <given-names>GJ</given-names>
   </name>, 
   <etal>et al.</etal>
  </person-group>
  <article-title>A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy</article-title>. 
  <source>Invest New Drugs</source>
  <year>2012</year>;
  <volume>30</volume>:
  <fpage>1591</fpage>–
  <lpage>6</lpage>.
  <pub-id pub-id-type="pmid">21863237</pub-id>
 </mixed-citation>
</ref>
